Xcout Intel
Crown Bioscience competitors & alternatives
The 12 closest competitors and alternatives to Crown Bioscience among biotechnology companies — ranked by similarity to what Crown Bioscience actually does, not by market-cap band.
Subscribe to see Crown Bioscience’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Crown Bioscience
Crown Bioscience is a global contract research organization (CRO) headquartered in California that specializes in translational oncology and immuno-oncology drug discovery and development. The company provides comprehensive discovery, preclinical, and translational research platforms.
Crown Bioscience at a glance
Crown Bioscience is a biotechnology company headquartered in United States, founded in 2006. Its most recent funding round, Series B, raised $3M in February 2008. Xcout tracks 10 named people at Crown Bioscience, including John Gu (Chief Executive Officer and Chief Operating Officer).
Crown Bioscience leadership
- John GuChief Executive Officer and Chief Operating Officer
- Eva HoChief Financial Officer
- Davy OuyangSenior Vice President, Innovation
- Shirley HuangSenior Vice President, Human Resource
- Zhaoxue (Luke) YuSenior Vice President, Global Scientific Operations
- Alexandra XuVice President, Legal Affairs
4 more named people on record for Crown Bioscience, with roles, board committees and tenure — see the full roster →
Crown Bioscience funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series B | $3M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 Crown Bioscience competitors
Ranked by semantic similarity — how close each company is to Crown Bioscience by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar biotechnology company
WuXi Biology provides a comprehensive spectrum of preclinical biology services and solutions for drug discovery, supporting clients from target discovery and validation to hit finding, lead optimization, and candidate selection. The company offers specialized platforms and expertise across major disease areas and therapeutic modalities, including small molecules, oligonucleotides, peptides, and antibodies.
Biotech
Biocytogen provides fully human antibody discovery services and preclinical contract research organization (CRO) services. The company offers genetically engineered animal models, cell lines, gene editing services, and in vivo and in vitro pharmacology studies to support biopharmaceutical research and drug development.
Biotech
Hubrecht Organoid Technology (HUB) develops patented patient-derived organoid technology from healthy and diseased tissues to predict patient responses to treatments. The company functions as a contract research organization (CRO), offering drug discovery services, custom model and assay development, clinical trials in a dish, and licensing programs for pharmaceutical and research applications.
Similar biotechnology company
Organoid Therapeutics, Inc. is a biotechnology contract research organization (CRO) that provides human brain tissue models, neuronal phenotyping, drug screening, and machine learning-based analytical services. The company serves pharmaceutical, biotech, and academic researchers by conducting pre-clinical research and translational studies to evaluate drug efficacy, neurotoxicity, and neurological disease models.
Biotech
Joinn Laboratories (China) Co., Ltd. delivers a comprehensive suite of preclinical and non-clinical services to clients across the United States, China, and other international regions. The company's business is organized into three core operational areas. Its Non-Clinical Studies Services segment focuses on drug safety assessment, drug metabolism and pharmacokinetics analysis, and pharmacology and efficacy investigations. The Clinical Trial and Related Services division offers contract research organization (CRO) support for clinical trials, co-manages Phase I clinical research units, and provides bioanalytical services. Furthermore, the Sales of Research Models segment is involved in the design, production, breeding, and distribution of various research models, including non-human primates and rodents. Beyond these offerings, Joinn Laboratories also provides investment management and cell-based assay (CBA) services. Founded in 1995, the company is headquartered in Beijing, China.
Biotech
Shin Nippon Biomedical Laboratories, Ltd. operates as a global contract research organization (CRO), delivering comprehensive drug discovery and development services both in Japan and internationally. Its preclinical offerings encompass a wide array of laboratory services, including regulatory-compliant good laboratory practice (GLP) inspections. These studies cover general and specialized toxicity assessments, detailed pathological examinations, pharmacokinetic (PK) and pharmacodynamic (PD) analysis for biopharmaceuticals, immunotoxicity testing, and antibody production. The company also conducts investigations into reproductive and developmental toxicity, pharmacological mechanisms, and efficacy, alongside providing various imaging services. Furthermore, the organization specializes in developing and validating analytical methodologies, analyzing biological specimens, and determining pharmacokinetic parameters. It also conducts studies on absorption, distribution, metabolism, and excretion (ADME), often utilizing radioisotope-labeled compounds. Beyond preclinical and analytical work, it extends its expertise to clinical trial support through site management organization (SMO) services and broader clinical contract research organization (CRO) support. Its translational research division focuses on advancing novel medical solutions, such as the development of nasal drug delivery systems, nucleic acid-based adjuvants, and regenerative medicine therapies. Established in 1957, Shin Nippon Biomedical Laboratories, Ltd. maintains its headquarters in Tokyo, Japan.
Biotech
Sai Life Sciences operates as a Contract Research, Development, and Manufacturing Organization (CRDMO) providing services from drug discovery to manufacturing. It serves pharmaceutical and biotech companies by offering capabilities in synthetic medicinal chemistry, biology, drug metabolism and pharmacokinetics, process development, and drug substance manufacturing.
Similar biotechnology company
Plato BioPharma, Inc. is a life sciences company headquartered in Westminster, Colorado, that offers expert preclinical drug discovery and pharmacological research services.
Biotech Services
Pharmaron Beijing Co., Ltd., together with its subsidiaries, operates as a pharmaceutical research and development service platform in North America, Europe, the Mainland China, Asia, and internationally. It operates through five segments: Laboratory Services; Chemical and Formulation Process Development and Manufacturing Services; Clinical Research Services; Macromolecule and Cell and Gene Therapy Services; and Others. The company offers laboratory chemistry and biological science services, including small molecule chemical drugs, oligonucleotides, peptides, antibodies, antimicrobial agents, antibody-drug conjugates (ADCs), and cell and gene therapy products; small molecule CDMO services, such as API process development and production, material science and preformulation, formulation development, and analytical development. It also provides clinical research services; macromolecular and cell and gene therapy services comprising drug discovery, development and production services, cell and gene therapy laboratory services, and gene therapy drug development and production services. In addition, the company is involved in the provision of technology development, technology transfer, technical consultation, technical services, and technical training; import and export of goods and technologies. Pharmaron Beijing Co., Ltd. was incorporated in 2004 and is headquartered in Beijing, the People's Republic of China.
Biotech
WuXi AppTec Co., Ltd. operates as an investment holding enterprise, delivering extensive research, development, and manufacturing services. These services primarily aid in the discovery, advancement, and production of small molecule pharmaceuticals, as well as sophisticated cell and gene therapies. The company maintains a global footprint, serving clients across the People's Republic of China, other Asian territories, the United States, Europe, and various international markets. Its operations are structured across six key segments: WuXi Chemistry, WuXi Testing, WuXi Biology, WuXi ATU, WuXi DDSU, and Others. The firm's comprehensive offerings encompass contract research, development, and manufacturing organization (CRDMO) services, supporting new drug development from initial discovery phases all the way to commercial launch. This scope extends to diverse synthetic molecular types, including small molecules, oligonucleotides, peptides, and complex conjugates. Furthermore, WuXi AppTec provides biology services and solutions that facilitate projects from target identification to candidate selection and subsequent clinical progression. The company also offers integrated drug and medical device testing services, covering everything from preclinical assessments to clinical trials. An end-to-end solution is available to expedite the market entry of cell and gene therapies, alongside specialized drug discovery services for pharmaceutical and biotechnology clients, and full-spectrum clinical research support. WuXi AppTec Co., Ltd. was established in 2000 and its headquarters are located in Shanghai, People's Republic of China.
Biotech
Champions Oncology, Inc. is dedicated to developing and commercializing cutting-edge technological products and services designed to personalize cancer treatment and streamline the development of oncology drugs across the United States. At the heart of its offerings is the Tumorgraft Technology Platform, an innovative approach that facilitates individualized cancer care by implanting human tumors into immune-deficient mice. Utilizing this proprietary platform, the company not only delivers personalized cancer solutions directly but also provides Translational Oncology Solutions, supporting pharmaceutical and biotechnology companies through their drug development lifecycle. Additionally, Champions Oncology offers Lumin Bioinformatics, a comprehensive software platform and data tool filled with insights from research services and clinical studies, accessible through annual subscriptions. The company distributes its offerings through various channels, including online platforms, word-of-mouth referrals, and a dedicated sales team, reaching both patients and healthcare professionals. Established in 1985, Champions Oncology, Inc. is based in Hackensack, New Jersey, and was formerly known as Champions Biotechnology, Inc. until its name change in April 2011.
Biotech
Selvita is an integrated contract research organization that provides comprehensive drug discovery and development services to the pharmaceutical and biotechnology industries. The company supports projects from target validation through preclinical candidate nomination and clinical trial batch manufacturing, specializing in small molecules, biologics, and agroscience under GMP and GLP standards.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Crown Bioscience and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Crown Bioscienceand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →